Background: Histologic subtypes of classical Hodgkin lymphoma (cHL) (e.g., nodular sclerosis
INTRODUCTION
Hodgkin lymphoma (HL) is a B-cell malignancy with complex, variable pathology (1) that has been classified by several histology schemes over time (2, 3) . The 1966 "Rye" modification of the Lukes-Butler classification, which described reproducible, clinically correlated subtypes (nodular sclerosis (NS), mixed cellularity (MC), lymphocyte depletion (LD), lymphocyte predominance (LP)), was used for nearly 30 years (1, 2) . In 1994, the Revised EuropeanAmerican Lymphoma (REAL) classification differentiated the etiologically distinct nodular LP In addition to having biological and prognostic differences (2, 3, 6-10), HL histologic subtypes show considerable epidemiologic variation (1, (11) (12) (13) (14) (15) (16) (17) (18) . For NS, the most common cHL subtype, incidence rates have been relatively stable over time (12, 19, 20) , whereas studies have documented persistently declining rates for MC (12, 20, 21) and increasing rates of cHL not otherwise specified (12, 20) , an ICD-O-3 category designating cHL without further histologic subtyping (hereafter called NOS). For MC, the second most common cHL subtype in the western world, decreasing rates could signal changes in the prevalence of risk factors (12, 21, 
22), including lower socioeconomic status (23, 24), HIV infection (25), other immunosuppression
As histologic heterogeneity is central to HL etiology and the accurate monitoring of its occurrence, understanding the persistent yet unexplained incidence trends for MC and NOS is important. Therefore, we evaluated detailed HL incidence rates by histologic subtype over the past 20 years, using population-based U.S. National Cancer Institute (NCI) Surveillance, Epidemiology and End Results (SEER) cancer registry data to provide the large case series needed for informative study of this uncommon disease. Further, for insight into diagnostic and classification issues pertinent to NOS rate increases, we reviewed diagnostic pathology reports for a regional subset of NOS cases. To obtain information about recent diagnostic and classification practices for NOS, we used data from a quality-control review at the Greater Bay Area Cancer Registry (a participant in the registry electronically). Among these cases, the 165 (57.7%) with electronic pathology reports and reviewed by a registry quality-control specialist did not differ significantly from the 121 not reviewed, according to chi-square tests, by age (four groups, p=0.11), gender (p=0.21), race/ethnicity (p=0.22), tumor site (p=0.55), or disease stage (p=0.37), but did differ by year of diagnosis (p<0.001), due to increasing electronic reporting over time. From the pathology report text, the reviewer classified each NOS diagnosis by factors related to diagnostic practice.
MATERIALS AND METHODS

We identified all new cases of primary cHL (ICD-
These included justification of the NOS classification, indication of specimen inadequacy for subtyping, subtype specification with insufficient definitiveness for coding per SEER requirements (32), subtype specification missed by coding registrars, biopsy type (excisional, core/fine needle aspiration (FNA)), biopsy site (lymph node, bone marrow), diagnosis facility (NCI-designated cancer center, integrated health system, other), location of final diagnosis (original diagnosing hospital, outside consultation), and existence of additional diagnostic studies.
Statistical Analysis
We computed average annual age-adjusted (to the 2000 US standard million population) HL incidence rates per 100,000 population and 95% confidence intervals (CI) for cHL overall, nLP, and cHL subtypes (as defined above), as well as for NS subtypes (the predominant category, NS NOS (code 9663), and the remaining categories NS cellular phase, grade 1, and grade 2 (codes 9664-9667).
We calculated rates by 10-year age group to capture HL age heterogeneity, and for the age groups 0-14, 15-39, 40-54 and 55 years and above (called "children", "adolescents/young adults (AYAs)", "middle-aged adults" and "older adults") to accommodate etiologic differences (33). We also calculated rates by gender, race/ethnicity (because of small numbers, we do not present AI/AN rates), stage (localized, regional, distant, unknown), tumor site (nodal, extranodal), year of diagnosis, and reporting SEER registry. To evaluate time trends, we calculated annual incidence rates and conducted Joinpoint (segmented linear) regression analysis, which identifies specific significant changes in annual rates over time and calculates the annual percent change (APC) and associated 95% CI in rates within each trend segment (34). We also calculated incidence rates for four five-year time periods (1992-96, 1997-2001, 2002-06, 2007-11) for cHL, cHL subtypes and nLP (Supplemental Table 1 ), and for NS subtype groups (Supplemental Table 2 ). We compared five-year rates in order to a) summarize the overall magnitude of a change, b) quantify change when sample sizes prevented calculation of an APC, or c) compare rates for two specific five-year periods.
For these purposes, we calculated incidence rate ratios (IRRs), considering as significant any differences for which the IRR 95% CI did not include 1; all IRRs presented reflect comparisons to the 1992-96 rate unless otherwise indicated.
To examine the possibility that the previously described opposing incidence trends for MC and NOS rates (12, 20) reflected increasing incorporation of true MC diagnoses into NOS over time, we 1) compared age-specific rates of MC and NOS in the earliest and latest five-year time periods (1992-96, 2007-11), using IRRs to evaluate whether differences in subtype rate patterns diminished, consistent with a case transfer; and 2) calculated rates, and used Joinpoint to examine trends, for MC and NOS combined, postulating that a lack of significant trends for this grouped category would support a case transfer. We repeated both analyses by also combining LD cases, since they may be considered grades of one subtype (2) , and the NS subtype group 9664-9667, as pathology practices around their use have changed over time (35, 36).
We characterized NOS diagnostic practice using chi-square or Fisher's exact tests to examine cases by registry patient and tumor characteristics and quality-control study factors, focusing on biopsy type because core/FNA biopsies have been associated with difficulties in diagnosing HL (37)).
We used SEER*Stat software (38) to calculate rates, Joinpoint Regression Program version 4.0.4 for Joinpoint analyses, and SAS version 9.3 for descriptive statistics. All analyses had the oversight of the institutional review board at the Cancer Prevention Institute of California.
RESULTS
Incidence trends for cHL and nLP
Overall age-adjusted incidence rates of cHL were stable until 2007, when they began to decline ( . APCs showed that rates also declined in almost all regional registries (Table 1) .
LD:
Decreases occurred in rates overall, and for males, whites, older adults, localized and distant stages (IRR, 2007-11: 0.59 (0.36, 0.95)) and nodal disease.
LR: LR incidence declined significantly among older adults (Table 1) Table 1 Table 3 (first column) shows minimal (<1%) annual change overall) but significant increases for females and blacks after 2000, for whites and APIs over the study period, and for AYAs starting in 1998 after a prior decline. Very similar patterns occurred in combined rates also including LD (Table 3 , second column). With the addition of NS 9664-9667 (Table 3 , third column), trends in combined rates were seen only for persons over age 80, and for localized and regional disease. 
Review of original pathology reports for NOS-coded cases
DISCUSSION
In the most recent two decades of SEER data, cHL incidence rates overall were stable until 2007, then showed the first downturn in many years (12) . Among cHL subtypes, NS had rates that were unchanged over the first 15 study years before declining, with variation in trends by gender and age; similar patterns and variation for the most common NS subtype (code 9663) are suggestive of a true incidence change. In contrast, rate decreases for MC and increases for NOS were seen largely irrespective of patient gender, age group, race/ethnicity, tumor stage and site, and SEER registry-a uniformity suggestive of artifactual changes. Growing classification of true MC as NOS over time was suggested by the opposing directions of the MC and NOS incidence trends, the similarity of age-specific incidence rates of NOS for 2007-11 and MC for 1992-96, and the minimal temporal increases in combined MC/NOS rates overall.
Further, the uniform declines in the less common subtypes LD and NS codes 9664-9667, and the virtual absence of trends in rates also including these subtypes, support similar Trends in histology-specific HL rates could be a consequence of secular changes in risk factors.
For the predominant NS category, recent declines could reflect changes in environments fostering early-life social isolation, which has been established to affect HL risk in young adults (53-59). Some of these factors (e.g., family size and birth order) have had decreasing importance to HL risk, likely because of changing prevalences resulting from demographic shifts (54, 60-64). However, preschool attendance has emerged as a protective factor (54). For the AYA birth cohorts in this study period, the rising percentages of children under age 5 in daycare or preschool (i.e., 8%, 15%, 20%, 30%, 31%, 28%, and 35% in 1965, 1977, 1982, 1988 , 1991 and 1993, respectively (65)) are consistent with the observed declines in AYA NS rates. However, these attendance data do not speak to the gender differences in NS rate declines, which are consistent with well described but little understood gender differences in young-adult HL incidence, including cohort effects (52).
For MC, which is associated with lower socioeconomic status (23, 24), a general rise in the standard of living could have contributed to the rate decline, although SES changes in the U.S. over the study period have not been substantial. Changes in HIV infection prevalence also could have affected observed rates (25, 66). Since 1992, the incidence of new HIV infections in the U.S. increased and then stabilized (67); highly active anti-retroviral therapies introduced in the mid-1990s may have lessened HL risk, although their impact remains unclear (25).
However, the occurrence of MC rate decreases across gender and age groups, and the low proportion of HIV-positive MC cases (10% of males (25)), suggest that the observed MC trends are not largely attributable to HIV infection. In SEER data restricted to California (38% of all study cases), overall MC rates (n=7,485) decreased whether the 515 cases with HIV/AIDS (68) were included (APC=-4.2 (-5.3, -3.1) for 1992-2011) or excluded (APC =-4.1 (-5.2, -3.1) for 1992-2011). Long-standing decreases in cigarette smoking prevalence (69) could have contributed to the observed rate decreases (28). MC rates also could be declining due to increasing westernization of immigrants, in whom MC risk is elevated (24, 70). However, we observed no differences in MC trends between whites and Hispanics or APIs, populations with large immigrant subgroups (70, 71) . Further, in California data (70) , MC rates declined between 1988-92 and 2000-04 similarly for whites, US-born Hispanics, and foreign-born Hispanics (data not shown).
Thus, artifact likely underlies the trends noted here, reflecting changes in diagnostic and/or classification practice. Changes in diagnostic practice have occurred with the advent of core needle biopsies and FNA in place of excisional biopsies (72) . While less invasive, these new methods yield a smaller quantity and often lower quality of tumor tissue, specifically the tissue preserving tumor architecture; indeed, our review of NOS pathology reports found specimen inadequacy for subtyping mentioned in 12% of cases. This consequence of core/FNA biopsies could result in poorer diagnostic specificity for HL (73) , given the difficulties of diagnosing HL with these methods (37). Diagnostic specificity due to lower quality specimens would be more likely to occur with MC than NS, since characteristic morphology of the latter often is retained in the needle biopsy. Gradual adoption of the new biopsy methods is consistent with our findings of similarities in later NOS to earlier MC rates, presumably as the decreasing ability to diagnose MC (and LD (74) This study used a large database that permitted detailed evaluation of histology-specific rates, and whose high-quality population-based data with standardized coding yielded reliable findings generalizable to similar populations. Our pathology report review provided preliminary insights into diagnostic and classification practices for NOS. However, we were unable to evaluate the impact on histology rate trends of facility type, a factor previously associated with diagnostic accuracy of lymphomas (75), or of facility type and case volume, factors related to the specificity of histologic typing for other cancers (76) . As our NOS quality-control review occurred in a single regional registry for a recent time period, it cannot speak to more widespread diagnostic practices or trends over time.
Diminishing specificity of histologic subtyping for cHL has important implications. For epidemiology, it renders histology-specific incidence rates difficult to interpret and confounds secular trends. Despite lacking a biological definition, NOS must be included as a subtype in HL research, as it is now the second most common cHL category. The potential to HL etiology of subtype differences in gene expression profiling (6) 
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